Technology
Health
Biotechnology

Onconova Therapeutics

$3.25
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-2.75%) Today
+$0.07 (2.20%) After Hours

Why Robinhood?

You can buy or sell ONTX and other stocks, options, ETFs, and crypto commission-free!

About

Onconova Therapeutics, Inc. Common Stock, also called Onconova Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. Read More It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Employees
25
Headquarters
Newtown, Pennsylvania
Founded
1998
Market Cap
18.55M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
126.79K
High Today
$3.37
Low Today
$3.12
Open Price
$3.30
Volume
6.51K
52 Week High
$11.17
52 Week Low
$1.69

Collections

Technology
Health
Biotechnology
Therapy
Medical
Biopharmaceutical
Cancer Prevention
Pharmaceutical

News

Seeking AlphaMay 13

Onconova up 11% premarket on rigosertib deal in China

Thinly traded nano cap Onconova Therapeutics (NASDAQ:ONTX) is up 11% premarket on increased volume in reaction to its license agreement with HanX Biopharmaceuticals to develop and commercialize products in China, including rigosertib.

153
NasdaqMay 7

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Tuesday, May 14, 2019 NEWTOWN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that the Company will release its first quarter 2019 financial results on Tuesday, May 14, 2019 before the market ope...

54
Markets InsiderMay 6

Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark

NEWTOWN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that five posters related to the Company's lead product candidate, rigosertib, were accepted for presentation at the 15th International Symposium on Myelodysplastic Syndromes taking place May 8-11, 2019 at the Tivol...

33

Earnings

-$1.29
-$0.88
-$0.48
-$0.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$1.03 per share
Actual
-$1.29 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.